http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-579764-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dae6faca0f6a059c3befa58d4f8955c |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
filingDate | 2008-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afe76cf5d2e099c0c92786437d285bfe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a40be521bd9dc9a75d880f6790d2e60b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bda8e06a0c72e23a2cb4b47aeb91735b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8b306485cb345a48e1329f7830f693f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_404788fa046481bf99dafa77285aafb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be23de7421dd711b3d437f6a381f54c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0564af6d060241844f8a9ab461afc3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e104e24848ba1031968e3618466d9cd4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f379426e8f211c6575b1eafb4f4a0738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c19d3bb0a26a4c0ba7a0d2baea0b46f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d67fa0f13fd7ac60476c25cfbd37384 |
publicationDate | 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | NZ-579764-A |
titleOfInvention | 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators |
abstract | Disclosed are 8-oxy quinoline compounds of formula I, salts thereof, and methods for their preparation. Specific examples of compounds of formula I include: 1-{ 4-Chloro-3-[4-(4-fluoro-pyrazol-1-yl)-2-methyl-quinolin-8-yloxymethyl]-6-methylpyridin-2-ylmethyl} -2-oxo-1,2-dihydro-pyridine-3-carbonitrile, 1-{ 3-[4-(5-Chloro-thiazol-4-yl)-2-methyl-quinolin-8-yloxymethyl]-4-methyl-pyridin-2-ylmethyl} -3-trifluoromethyl-1H-pyridin-2-one, N-(5-{ 8-[4-Chloro-2-(2-oxo-3-trifluoromethyl-2H-pyridin-1-ylmethyl)-pyridin-3-ylmethoxy]-2-methyl-quinolin-4-yl} -1H-pyrazol-4-ylmethyl)-acetamide, and 1-{ 4-Chloro-3-[4-(4-hydroxy-1H-pyrazol-3-yl)-2-methyl-quinolin-8-yloxymethyl]-6-methyl-pyridin-2-ylmethyl} -2-oxo-1,2-dihydro-pyridine-3-carbonitrile. Also disclosed is the use of compounds of formula I for inhibiting binding of BK to a BK B2 receptor and the use of detectably labelled compounds of formula I for localizing or detecting a BK B2 receptor in a tissue. Compounds of formula I are useful for treating skin disorders; eye diseases; ear diseases; mouth, throat and respiratory diseases; gastrointestinal diseases; liver, gallbladder and pancreatic diseases; urinary tract and kidney diseases; diseases of male genitale organs and female genitale organs; diseases of the hormone system; metabolic diseases; cardiovascular diseases; blood diseases; lymphatic diseases; disorders of the central nervous system; brain disorders; musculoskeletal system diseases; allergy disorders; pain; infectious diseases; inflammatory disorders; injuries; immunology disorders; cancers; hereditary diseases; or edema. |
priorityDate | 2007-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 792.